Article of the day, August 31st, suggested by the Immune Oncology Research Institute
Immune Oncology Research Institute shared a post on LinkedIn:
“Article of the day! Suggest by the Immune Oncology Research Institute.
Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer
Authors: Ramez N. Eskander, Michael W. Sill, Lindsey Beffa, Richard G. Moore, Joanie M. Hope, Fernanda B. Musa, Robert Mannel, Mark S. Shahin, Guilherme H. Cantuaria, Eugenia Girda, Cara Mathews, Juraj Kavecansky, Charles A. Leath III, Lilian T. Gien, Emily M. Hinchcliff, Shashikant B. Lele, Lisa M. Landrum, Floor Backes, Roisin E. O’Cearbhaill, Tareq Al Baghdadi, Emily K. Hill, Premal H. Thaker, Veena S. John, Stephen Welch, Amanda N. Fader, Matthew A. Powell, Carol Aghajanian.
Author Affiliations: UC San Diego Health – Moores Cancer Center, Roswell Park Comprehensive Cancer Center ,Wilmot Cancer Institute ,University of Rochester Medical Center ,Memorial Sloan Kettering Cancer Center ,Weill Cornell Medicine, Case Comprehensive Cancer Center, The Ohio State University Wexner Medical Center, James Cancer Hospital, ALASKA WOMEN’S CANCER CARE, University of Oklahoma, Abington Hospital – Jefferson Health ,Rutgers Cancer Institute, Women & Infants Hospital, The Warren Alpert Medical School of Brown University, Deep South Center for Occupational Health and Safety, UAB O’Neal Comprehensive Cancer Center, ROBERT H. LURIE COMPREHENSIVE CANCER CENTER OF NORTHWESTERN UNIVERSITY, IU Simon Comprehensive Cancer Center, UNIVERSITY OF IOWA HOSPITALS &CLINCS, et al.
Source: Immune Oncology Research Institute/LinkedIn
Immune Oncology Research Institute (IMMONC), established in 2022, is a non-profit, independent, patient-centered research institute. The mission of IMMONC is to advance the cancer knowledge and care through breakthrough scientific research, to integrate innovative immune-oncology therapies into the clinical practice for different types of cancers, to generate and collect clinical data for the identification of new therapeutic targets, developing predictive models and optimizing patient outcomes, to increase the availability and accessibility of those discoveries for the cancer patients, to create a world-class professional environment, to attract the brightest minds in cancer field and to train the next generation researchers.
Other posts featuring Immune Oncology Research Institute on OncoDaily.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023